Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery

Drug Delivery

Volumn 23, Issue 8, 2016, Pages 2720-2725

  Wu, Miaojing ^a   Fan, Yanghua ^a   Lv, Shigang ^a   Xiao, Bing ^a   Ye, Minhua ^a   Zhu, Xingen ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Co delivery; combined chemotherapy; glioblastoma multiforme; nanostructured lipid carriers; solid lipid nanoparticles

Indexed keywords

DRUG CARRIER; NANOSTRUCTURED LIPID CARRIER; SOLID LIPID NANOPARTICLE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE; LIPID; NANOMATERIAL; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLIOMA; HUMAN; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MEDICINAL CHEMISTRY; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DACARBAZINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; GLIOMA; HUMANS; LIPIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NANOSTRUCTURES; PARTICLE SIZE; VINCRISTINE;

EID: 84996587567     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1058434     Document Type: Article

References (23)

1. Alam MI, Baboota S, Ahuja A, et al. (2013). Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Drug Deliv 20:247–5
2. Barua NU, Hopkins K, Woolley M, et al. 2014. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. Drug Deliv. [Epub ahead of print]. doi:10.3109/10717544.2014.908248
3. Bothun GD, Lelis A, Chen Y, et al. (2011). Multicomponent folate-targeted magnetoliposomes:design, characterization, and cellular uptake. Nanomedicine 7:797–805
4. Buie LW, Valgus JM. (2012). Current treatment options for the management of glioblastoma multiforme. Hematol Oncol Pharm 2:57–63
5. Chen M, Chen R, Wang S, et al. (2013). Chemical components, pharmacological properties, and nanoparticulate delivery systems of Brucea javanica. Int J Nanomedicine 8:85–92
6. Doktorovova S, Souto EB, Silva AM. (2014). Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers–a systematic review of in vitro data. Eur J Pharm Biopharm 87:1–18
7. Fathi-Azarbayjani A, Ng KX, Chan YW, et al. (2015). Lipid vesicles for the skin delivery of diclofenac:cerosomes vs. other lipid suspensions. Adv Pharm Bull 5:25–33
8. Greco F, Vicent MJ. (2009). Combination therapy:opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 61:1203–13
9. Higa M, Katagiri C, Shimizu-Okabe C, et al. (2015). Identification of a novel cell-penetrating peptide targeting human glioblastoma cell lines as a cancer-homing transporter. Biochem Biophys Res Commun 457:206–12
10. Jiang Z, Sun C, Yin Z, et al. (2012). Comparison of two kinds of nanomedicine for targeted gene therapy:premodified or postmodified gene delivery systems. Int J Nanomedicine 7:2019–31
11. Mattingly SJ, O'Toole MG, James KT, et al. (2015). Magnetic nanoparticle-supported lipid bilayers for drug delivery. Langmuir 31:3326–32
12. Messaoudi K, Saulnier P, Boesen K, et al. (2014). Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. Int J Nanomedicine 9:1479–90
13. Müller RH, Shegokar R, Keck CM. (2011). 20 Years of lipid nanoparticles (SLN and NLC):present state of development and industrial applications. Curr Drug Discov Technol 8:207–27
14. Sarisozen C, Vural I, Levchenko T, et al. (2012). Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv 19:363–70
15. Saupe A, Wissing SA, Lenk A, et al. (2005). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)–structural investigations on two different carrier systems. Bio-Med Mater Eng 15:393–402
16. Stupp R, Mason WP, van den Bent MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96
17. Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin:comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43
18. Vlachostergios PJ, Papandreou CN. (2015). Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells:a flow cytometric analysis. Arch Med Sci 25;11:307–10
19. Wissing SA, Kayser O, Müller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72
20. Yang XY, Li YX, Li M, et al. (2013). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334:338–45
21. Zaki NM. (2014). Augmented cytotoxicity of hydroxycamptothecin-loaded nanoparticles in lung and colon cancer cells by chemosensitizing pharmaceutical excipients. Drug Deliv 21:265–75
22. Zhang B, Dou Y, Xu X, et al. (2015). Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells. Int J Clin Exp Med 15;8:1792–802
23. Zhang T, Zheng Y, Peng Q, et al. (2013). A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect:in vitro and in vivo studies. Int J Nanomedicine 8:1185–96